CTOs on the Move


 
Wisq is a space for life at work. The Wisq platform helps employees improve social well-being by enabling them to connect, share and build relationships at work. Organizations increase employee engagement, improve belonging and retention and build happy work cultures. Wisq enables smart profiles, intuitive sharing, community building and audio lounges for informal hangouts. Based in Redwood City, CA, the company was founded by three former Glint executives: Jim Barnett, chief executive officer; Goutham Kurra, chief product officer; and Chih-Po Wen, chief technology officer. Wisq has raised more than $40 million and is backed by True Ventures, Norwest Venture Partners ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.wisq.com
  • 835 Main Street
    Redwood City, CA USA 94063
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

M3

The best back-office hosted software solution provider for the Hospitality Industry. We provide accounting, business intelligence, and payroll solutions across all brands and independent hotels in the U.S. and Canada. Our enterprise level solution allows franchisees access to their financial and operating information in real-time with user friendly reports. Our clients are able to reduce overhead and labor by leveraging our solutions to remain competitive in the industry.

Acima Credit

Buy what you need today with no credit financing. Get 12 months to pay, regardless of credit score. Instant decisions. Apply online, on your mobile device, or at your favorite store. We offer easy payment options, giving you the chance to build your cr...

Veracross

A school information system based on a single, fully integrated database, providing a platform for the future, all delivered with exceptional service.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.

ConnexPay

Transforming Payment Acceptance & Issuance